Emma Albee knows the experimental drug she takes is not a cure. It won’t allow her to stop using the wheelchair she’s relied on since adolescence, and it’s not going to take away the latticework of bone that has locked her hips in place.
But for Albee and the roughly 1,000 people with a rare genetic disorder that causes their body to grow rigid bone where it doesn’t belong, the drug symbolizes a future in which years of research, advocacy, and tireless fundraising might bring about a multitude of medicines for what is now an untreatable disease.
“Even if it’s not the perfect drug, to have something where there’s data to show that it helps, that’s just so important,” said Albee, 34.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect